IET Lucknow's Special Carry Over Examination 2021-22

The examination form for the special carry-over examination 2021-22 of the Institute of Engineering and Technology can be filled latest by September 20, 2022.

Institute of Engineering and Technology, Lucknow is conducting a special carry-over examination 2021-22 for the pass-out batch of the previous session of 2021-22 in September 2022. As per the official notification, interested candidates can fill out the examination form latest by September 20, 2022. The form will be filled out online at https://eforms.ietlucknow.ac.in/node/21.

The examination fee of INR 1000 per carry-over subject needs to be paid by NEFT/IMPS transfer and a soft copy of payment in pdf format needs to be uploaded with the examination form. The examination fee is to be sent to the following account-

• Bank Name: Bank of Baroda  
• Branch : I E T MOHIBULLAPUR, LUCKNOW 
• Account Number: 79300100005072
• Account Type: Saving (SB)
• Account Holder: Director IET LUCKNOW 
• IFSC Code: BARB0VJIETM (Note that 5th alphabet from left in IFSC Code is Zero)

If candidates face any issues while filling out the examination form, they can contact the deputy controller on phone at - 7007896069 and the students can also personally visit the department. 

"To fill the examination form before the deadline is the responsibility of students," said the official notification.

Eligibility Criteria

The notification stated that only candidates with the following eligibility can apply for the special carry-over examination 2021-22 of the Institute of Engineering and Technology, Lucknow:

Only the students whose odd and even semester results are announced can apply.

Those who have given the last year's examination at least once and in the previous year's result, there is PCP/PCP-A status.

The students who will appear in the special carry-over examinations will be considered from session 2021-22 only.

Read more:

• IIT Delhi: Be a changemaker; Apply to Robotics for Impact by Sept 25
• IIT Bombay's CAR-T cell therapy shows promising early signs of efficacy in blood cancer treatment